



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re Application of: White et al.)	I hereby certify that this paper is being
· ·)	deposited with the United States Postal
Serial No: 09/994,185)	Service as First Class Mail, postage prepaid
)	in an envelope addressed to: Commissioner
Filed: November 26, 2001)	for Patents, Washington, D.C. 20231, on
,)	this date:
For: "Method for Quantifying LBP in)	D# 5
Body Fluids")	February 25, 2002
•)	
Group Art Unit: TBD)	$I(I) \cap Q$
•)	My Duy
Examiner: TBD)	Jeffrey B. Sharp
)	Registration No. 31,879
	·	Attorney for Applicants

INFORMATION DISCLOSURE STATEMENT WITH PTO-1449 FORM

Commissioner for Patents Washington, DC 20231

Sir:

In compliance with 37 C.F.R. §1.97 and the duty of disclosure under 37 C.F.R. §1.56, the attached form PTO-1449 is hereby submitted by the Applicants for consideration in connection with the above-identified patent application. Pursuant to 37 C.F.R. §1.98(d), copies of the documents cited on the PTO-1449 form are not being provided because they were previously cited by or submitted to the Patent Office in grandparent application U.S. Serial No. 08/779,400 or great grandparent application U.S. Serial No. 08/377,391, from which priority is claimed under 35 U.S.C. §120. Should the Examiner desire additional copies of the documents, Applicants will provide them upon request.

This Information Disclosure Statement is not intended to be an admission that a search has been made, that other relevant art does not exist, or that any of the information disclosed herein constitutes prior art under 35 U.S.C. §102 or 35 U.S.C.§103.

This Information Disclosure Statement is submitted within three months of the filing date and before the receipt of an Office Action on the merits of the above-identified

application and consequently should be considered by the Patent Office without payment of a fee. See 37 C.F.R. §1.97(b). However, please charge any necessary fees due in connection with this Information Disclosure Statement to Deposit Account No. 13-2855. A copy of this paper is enclosed herewith.

MARSHALL, GERSTEIN & BORUN

6300 Sears Tower

233 South Wacker Drive

Chicago, Illinois 60606-6402

(312) 474-6300

By

Jeffrey 3. Sharp

Registration No.: 31,879 Attorney for Applicants

February 25, 2002

Form PTO-1449 (Modified) MAR 0 5 2002 INFORMATION DISCE OSURE STATEMENT

U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No. 27129/33783B Serial No. 09/994,185

Applicant

White et al.

Filing Date November 26, 2001 Group **TBD**

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS							
*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	A1	5,484,705	01/16/96	White			
	A2	5,245,013	09/14/93	Ulevitch			
	A3	5,310,879	05/10/94	Ulevitch			

FOREIGN PATENT DOCUMENTS								
					Translation			
*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Yes	No
	B1	WO 91/01639	02/21/91	PCT				
	B2	WO 93/06228	04/01/93	PCT				
	В3	WO 94/21280	09/29/94	PCT	·			
	B4	WO 94/25476	11/10/94	PCT				
	B5	WO 95/00641	01/05/95	PCT	<u></u>			
	В6	WO 95/02414	01/26/95	PCT				
			L	_ 	1	<u> </u>	<u> </u>	<u> </u>

FX	Δ	M	IN	FR	•

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified) INFORMATION DISC STATEMENT

U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No. 27129/33783B

Sérial No. 09/994,185

Applicant

White et al.

Filing Date

Group

(Use several sheets if necessary)

November 26, 2001 **TBD**

	(OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
	C 1	Dofferhoff et al., "Tumor necrosis factor (cachectin) and other cytokines in septic shock: a review of the literature", Netherlands J. Med., 39:45-62 (1991).
	C2	Elsbach <i>et al.</i> , "Separation and Purification of a Potent Bactericidal/Permeability-increasing Protein and a Closely Associated Phospholipase A ₂ from Rabbit Polymorphonuclear Leukocytes", <i>J. Biol. Chem.</i> , 254(21):11000-11009 (November 10, 1979).
-	C3	Erwin and Munford, "Plasma Lipopolysaccharide-Deacylating Activity (Acyloxyacyl Hydrolase) Increases After Lipopolysaccharide Administration to Rabbits", <i>Lab. Invest.</i> , 65(2):138-144 (1991).
	C4	Gallay et al., "Purification and Characterization of Murine Lipopolysaccharide-Binding Protein", <i>Infect. Immun.</i> 61(2):378-383 (February 1993).
	C5	Gazzano-Santoro <i>et al.</i> , "High-Affinity Binding of the Bactericidal/Permeability-Increasing Protein and a Recombinant Amino-Terminal Fragment to the Lipid A Region of Lipopolysaccharide", <i>Infect. Immun. 60(11):</i> 4754-4761 (November 1992).
	C6	Leturcq et al, "Generation of Monoclonal Antibodies to Human LBP and Their Use in the Detection of LBP Protein in Serum", J. Cell. Biochem., 16C:161 (1992).
	C7	Marra et al., "The Role of Bactericidal/Permeability-Increasing Protein as a Natural Inhibitor of Bacterial Endotoxin", J. Immun., 148(2):532-537 (January 15, 1992).
	C8	Pereira et al, "Quantitation of a cationic antimicrobial granule protein of human polymorphonuclear leukocytes by ELISA", J. Immunol. Methods, 117:115-120 (1989).
	С9	Pesce et al., "Cationic antigens Problems associated with measurement by ELISA", J. Immunol. Methods, 87:21-27 (1986).
	C10	Schindler <i>et al.</i> , "Plasma levels of bactericidal/permeability-increasing protein (BPI) and lipopolysaccharide-binding protein (LBP) during hemodialysis", <i>Clin. Nephrology</i> , 40(6):346-351 (1993).

EXAMINER	DATE CONSIDERED

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified) INFORMATION RISCLO **TRE STATEMENT**

U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No. 27129/33783B Serial No. 09/994,185

Applicant

White et al.

Filing Date

Group

(Use several sheets if necessary)

November 26, 2001 TBD

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
C11	Schumann et al., "Structure and Function of Lipopolysaccharide Binding Protein", Science, 249:1429-1433 (September 21, 1990).
C12	Spitznzgel, "Antibiotic Proteins of Human Neutrophilia", J. Clin. Invest., 86:1381-1386 (1990).
C13	Taber et al., Taber's Cyclopedic Medical Dictionary, pp 545 (F.A. Davis Co., Philadelphia) (1985).
C14	Ulevitch, Presentation at the merican Society of Microbiology General Meeting in Atlanta, Georgia (May 16-21, 1993).
C15	von der Mohien et al., Bactericidal/Permeability-Increasing Protein Levels Predict Survival in Patients with Gram-Negative Sepsis", Abstract presented at 13th International Symposium on Intensive Care and Emergency Medicine, (Brussels, Belgium) (March 1993).
C16	Weiss and Olsson, "Cellular and Subcellular Localization of the Bactericidal/Permeability-Increasing Protein of Neutrophils", <i>Blood</i> , 69(2):652-659 (February 1987).
C17	Weiss et al., "Human Bactericidal/Permeability-Increasing Protein and a Recombinant NH ₂ - Terminal Fragment Cause Killing of Serum-resistant Gramnegative Bacteria in Whole Blood and Inhibit Tumor Necrosis Factor Release Induced by the Bacteria", "J. Clin. Invest. 90:1122-1130 (September 1992).
C18	Weiss et al., "Purification and Characterization of a Potent Bactericidal and Membrane Active Protein from the Granules of Human Polymorphonuclear Leukocytes", J. Biol. Chem., 253(8):2664-2672 (April 25, 1978).
C19	White et al., "Measurement of bactericidal/permeability-increasing protein in human body fluids by sandwich ELISA", J. Immunol. Methods, 167:227-235 (1994).
C20	Wright et al., "CD14, a Receptor for Complexes of Lipopolysaccharide (LPS) and LPS Binding Protein", Science, 249:1431-1433 (September 21, 1990).
C21	Ulevitch, Presentation at the American Society of Microbiology General Meeting in Atlanta, Georgia (May 16-21, 1993) (Session 13 Abstract 564).

· · · · · · · · · · · · · · · · · · ·	
EXAMINER	DATE CONSIDERED

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SHEET 4 OF 5 Form PTO-1449 (Modified) U.S. Department of Commerce Atty. Docket No. Serial No. Patent and Trademark Office 09/994,185 27129/33783B Applicant INFORMATION DI White et al. URE STATEMENT Filing Date Group November 26, 2001 **TBD** (Use several sheets if necessary)

•	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
C22	Tobias et al., "Lipopolysaccharide Binding Protein" J. Cell. Biochem., 16 C:151 (Abstract (CB006) (1992)
C23	Ballou et al., "Laboratory Evaluation of Inflammation," <i>Textbook of Rheumatology</i> , Vol. 1, Ch. 40, pp. 671-679 (1993)
C24	Baumann et al., "The acute phase response," <i>Immunology Today</i> , Vol. 15, ¼½. 2, pp. 74-80 (1994)
C25	Grube et al., "Lipopolysaccharide Binding Protein Expression in Primary Human Hepatocytes and HepG2 Hepatoma Cells*," <i>J. Biol. Chem.</i> , Vol. 269, No. 11, pp. 8477-8482 (1994)
C26	Raynes, "Carbohydrate Binding Proteins and Immune Responses," Biochemical Immunology Group/Glycobiology Group Joint Colloquium Organized by G.B. Wisdom and M.I. Halliday (The Queen's University, Belfast) and Edited by G.B. Wisdom. 648th Meeting held at the Queen's University, Belfast, 14-17 September 1993, Biochemical Society Transactions, Vol. 22, pp. 69-74 (1994)
C27	Meszaros et al., "Immunoreactivity and Bioactivity of Lipopolysaccharide-Binding Protein in Normal and Heat-Inactivated Sera," <i>Infection and Immunity</i> , Vol. 63, No. 1, pp. 363-366 (1995)
C28	Pugin et al., "Soluble CD14 and Lipopolysaccharide Binding Protein Mediate Epithelial Cell Responses to Lipopolysaccharides," FASEB J., A142 (1993)
C29	Geller et al., Arch. Surg., 128:22-28 (1993)
C30	Tobias, J. Biol. Chem., 263:13479-13481 (1988)
C31	Schumann, Science, 249:1429-1431 (1990)
C32	Dubin et al., "Asthma and Endotoxin: Lipopolysaccharide-Binding Protein and Soluble CD14 in Bronchoalveolar Compartment," Am. J. Physiol., 270:L736-L744 (1996)
C33	Froon et al., "Lipopolysaccharide Toxicity Regulating Proteins in Bacteremia," <i>J. Infect. Dis.</i> , 171:1250-1257 (1995)

EXAMINER	DATE CONSIDERED
· ·	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



(Use several sheets if necessary)

U.S. Department of Commerce Patent and Trademark Office Atty. Docket No. 27129/33783B

Serial No. 09/994,185

Applicant

White et al.

Filing Date

November 26, 2001

Group **TBD**

 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)				
C34	Heumann et al., "Radioimmunoassay versus flow cytometric assay to quantify LPS-binding protein (LBP) concentrations in human plasma," <i>J. Immunol. Meth.</i> , 171:169-176 (1994)			
C35	Iriye et al., "Differences in the Concentration of an Endotoxin Binding Protein Help Explain Sensitivity to Septic Complications in Pregnancy," Am. J. Obstetrics Gynecol., 174(1 pt. 2):390 (1996)			
C36	Nakayama et al., "Monitoring Both Serum Amyloid Protein A and C-Reactive Proteins as Inflammatory Markers in Infectious Diseases," Clin. Chem. 39:293-297 (1993)			
C37	Schumann et al., 36th Int'l Conf. on Antimicrobial Agents and Chemotherapy, New Orleans, LA, September 15-18, (1996)			

TV A	MIN	TTD .
P.A.A	NIN	нк